ERBB2 and breast carcinoma: Perhapsthe next generation of prospective, translational research studies will incorporateboth venous and core biopsy sampling at time intervals as an endeavour to discoverprospective and stable circulating biomarkers, such as miRNAs, which may indicatepCR to therapies within HER2/neu overexpressing breast cancer.